ClinicalTrials.gg
Not yet recruitingNCT06051630Updated Sep 25, 2023

Effects of Perioperative Administration of Intravenous Lidocaine in Children Operated on for Acute Generalized Peritonitis

An interventional study of Lidocaine intravenous and Serum saline intravenous in Postoperative Pain, sponsored by Université NAZI BONI. Not yet recruiting. Open to participants aged 6 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-25.

Sponsored by Université NAZI BONI · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Nov 2023, 3 years ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
6 Years to 15 Years
Sex
All
01

Study summary

Intravenous administration of lidocaine perioperatively after laparotomy for peritonitis could be an interesting alternative by reducing the duration of postoperative ileus, the intensity of pain and the patient's hospital stay, as well as the cost of management in our context of lack of financial, technical and human resources, hence the present study.

02

Conditions studied

  • Postoperative Pain

Keywords

  • Peritonitis
  • Postoperative pain
  • Lidocaine
  • Burkina Faso
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's planned enrollment of 62 is below the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Université NAZI BONI is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients aged 6 to 15, Classified according to the American Society of Anaesthesiologists (ASA) (I, II and III) admitted for peritonitis and whose parents have given

Exclusion criteria

Exclusion Criteria:

  • State of shock
  • Severe renal insufficiency ( less than 30 ml/min)
  • History of allergy to lidocaine
  • Refusal to participate in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Lidocaine group

    The group will receive 1.5 mg/kg lidocaine 2% bolus, followed by a continuous electric syringe dose of 1.5 mg/kg/hour intraoperatively, then 1.5 mg/kg/hour during the first 24 hours postoperatively

    Drug: Lidocaine intravenous

  • Placebo comparator
    Saline group

    The control group will receive an equivalent volume of saline: the volume of saline to be administered will be obtained by considering the dose of lidocaine 2% that the patient would have received if he/she had been in the interventional group.

    Drug: Serum saline intravenous

Interventions

  • Perioperative lidocaine intravenous administration

  • DrugSerum saline intravenous

    Perioperative serum saline intravenous administration

06

What researchers measure

Primary outcomes

  1. Resumption of transit

    time to first gas and/or presence of bowel sounds

    Time frame: Up to 7 days during the postoperative period. From the date of randomization to the first postoperative gas and/or the presence of postoperative bowel sounds in the patient

Secondary outcomes

  1. Analog visual scale

    Average pain score, minimal value is 0, maximal value is 10 and higher score mean worse

    Time frame: Postoperative pain scores at 24 hours

  2. Concentration of C-reactive protein

    Average of C-reactive protein

    Time frame: Hours 24 postoperative

  3. Hospitalisation

    Number of days in hospital

    Time frame: Up to 30 days during the postoperative period. From the date of randomization to the patient's discharge from hospital or date of death

  4. Postoperative mortality

    Number of postoperative deaths

    Time frame: Up to 30 days during the postoperative period. From date of randomization to date of death

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06051630
Lead sponsor
Université NAZI BONI
Responsible party
Ismael Guibla (Principal investigator, Clinical doctor, Université NAZI BONI) — Principal investigator
First posted
Sep 25, 2023
Start date
Oct 1, 2023 (estimated)
Primary completion
Nov 1, 2023 (estimated)
Completion
Jan 1, 2024 (estimated)
Last update
Sep 25, 2023

Study contacts

Bertille KI, Doctor
Contact
bertilleki@yahoo.fr
+22670230257
Ismael GUIBLA, Doctor
Contact
ismaelguibla@gmail.com
+22676135113
Nazinigouba OUEDRAOGO, Professor
study director · JOSEPH KI-ZERBO University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion